Leap Therapeutics Inc
LPTX0.356USD
+0.050+16.24%
시장 운영 시간 （ET）시세는 15분 지연됩니다
14.74M시가총액
손실P/E TTM
자세한 내용은 Leap Therapeutics Inc 회사
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
회사 정보
종목 코드 LPTX
회사 이름Leap Therapeutics Inc
상장일Jan 24, 2017
CEOMr. Douglas E. (Doug) Onsi
직원 수52
유형Ordinary Share
회계 연도 종료Jan 24
주소47 Thorndike St, Suite B1-1
도시CAMBRIDGE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호02141
전화16177140360
웹사이트https://www.leaptx.com/
종목 코드 LPTX
상장일Jan 24, 2017
CEOMr. Douglas E. (Doug) Onsi
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
--
--
Ms. Patricia (Patty) Martin
Ms. Patricia (Patty) Martin
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
108.28K
+2.01%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Chairman of the Board
Chairman of the Board
23.05K
+10.21%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
-60.52%
Dr. Richard L. Schilsky, M.D.
Dr. Richard L. Schilsky, M.D.
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, May 17
마지막 업데이트: Sat, May 17
주주
주주 유형
주주
주주
비율
Gilead Sciences Inc
12.84%
Samsara BioCapital, LLC
5.89%
683 Capital Management LLC
3.50%
Acadian Asset Management LLC
3.09%
Beigene Ltd
2.93%
Other
71.75%
주주
주주
비율
Gilead Sciences Inc
12.84%
Samsara BioCapital, LLC
5.89%
683 Capital Management LLC
3.50%
Acadian Asset Management LLC
3.09%
Beigene Ltd
2.93%
Other
71.75%
주주 유형
주주
비율
Corporation
15.77%
Investment Advisor
10.39%
Venture Capital
7.58%
Hedge Fund
6.52%
Investment Advisor/Hedge Fund
4.34%
Individual Investor
0.58%
Research Firm
0.19%
Pension Fund
0.03%
Other
54.60%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
120
18.82M
45.42%
-6.51M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
2023Q2
173
10.09M
52.77%
+1.83M
2023Q1
168
6.01M
55.14%
-976.73K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Gilead Sciences Inc
5.32M
12.84%
--
--
Apr 21, 2025
Samsara BioCapital, LLC
2.44M
5.89%
--
--
Apr 21, 2025
683 Capital Management LLC
1.45M
3.5%
+99.90K
+7.40%
Mar 31, 2025
Acadian Asset Management LLC
1.28M
3.09%
+1.06M
+470.43%
Mar 31, 2025
Beigene Ltd
1.22M
2.93%
+1.22M
--
Oct 31, 2024
The Vanguard Group, Inc.
1.18M
2.84%
-15.38K
-1.29%
Mar 31, 2025
Monaco asset management S.A.M.
1.05M
2.53%
+844.13K
+410.02%
Mar 31, 2025
Simplify Asset Management Inc
950.97K
2.29%
+4.93K
+0.52%
Mar 31, 2025
Laurion Capital Management LP
709.22K
1.71%
--
--
Mar 31, 2025
HealthCare Ventures LLC
697.23K
1.68%
+20.91K
+3.09%
Apr 21, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Simplify Health Care ETF
0.19%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
Simplify Health Care ETF
비율0.19%
Avantis US Small Cap Equity ETF
비율0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
Dimensional US Core Equity 1 ETF
비율0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
날짜
유형
비율
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
Jun 20, 2023
Merger
10<1
